Metabolism of the vitamin D analog EB 1089: Identification of in vivo and in vitro liver metabolites and their biological activities∗
- 1 April 1997
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 53 (8) , 1087-1097
- https://doi.org/10.1016/s0006-2952(96)00816-7
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormoneBone, 1995
- Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP)Endocrine, 1995
- EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.Journal of Clinical Investigation, 1993
- EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitroBiochemical Pharmacology, 1992
- Calcipotriol (MC 903): Pharmacokinetics in rats and biological activities of metabolites: A comparative study with 1,25(OH)2D3Biochemical Pharmacology, 1991
- On the Mechanisms for the Selective Action of Vitamin D Analogs*Endocrinology, 1991
- Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidationBiochemical Journal, 1989
- The Role of the Vitamin D Endocrine System in Health and DiseaseNew England Journal of Medicine, 1989
- Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through the C-24 oxidation pathwayBiochemistry, 1989